Guideline for clinical comprehensive evaluation of Chinese patent medicine (2022 version) / 中国中药杂志
China Journal of Chinese Materia Medica
; (24): 256-264, 2023.
Article
Dans Zh
| WPRIM
| ID: wpr-970521
Responsable en Bibliothèque :
WPRO
ABSTRACT
Currently,the research or publications related to the clinical comprehensive evaluation of Chinese patent medicine are increasing,which attracts the broad attention of all circles. According to the completed clinical evaluation report on Chinese patent medicine,there are still practical problems and technical difficulties such as unclear responsibility of the evaluation organization,unclear evaluation subject,miscellaneous evaluation objects,and incomplete and nonstandard evaluation process. In terms of evaluation standards and specifications,there are different types of specifications or guidelines with different emphases issued by different academic groups or relevant institutions. The professional guideline is required to guide the standardized and efficient clinical comprehensive evaluation of Chinese patent medicine and further improve the authority and quality of evaluation. In combination with the characteristics of Chinese patent medicine and the latest research achievement at home and abroad,the detailed specifications were formulated from six aspects including design,theme selection,content and index,outcome,application and appraisal,and quality control. The guideline was developed based on the guideline development requirements of China Assoication of Chinese medicine. After several rounds of expert consensus and public consultation,the current version of the guideline has been developed.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Normes de référence
/
Médicaments issus de plantes chinoises
/
Chine
/
Consensus
/
Médicaments sans ordonnance
/
Médecine traditionnelle chinoise
Pays comme sujet:
Asia
langue:
Zh
Texte intégral:
China Journal of Chinese Materia Medica
Année:
2023
Type:
Article